Document:

EXHIBIT 10.15

     THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF
     THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
     AS AMENDED, OR ANY STATE SECURITIES LAWS. THIS WARRANT AND THE COMMON
     STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED
     FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE
     REGISTRATION STATEMENT AS TO THIS WARRANT AND THE COMMON STOCK ISSUABLE
     UPON EXERCISE OF THIS WARRANT UNDER SAID ACT AND ANY APPLICABLE STATE
     SECURITIES LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO AMS
     HEALTH SCIENCES, INC. THAT SUCH REGISTRATION IS NOT REQUIRED.

           Right to Purchase up to 2,272,727 Shares of Common Stock of
                            AMS Health Sciences, Inc.
                   (subject to adjustment as provided herein)

                          COMMON STOCK PURCHASE WARRANT

No. _________________                               Issue Date:  June 28, 2006

     AMS Health Sciences, Inc., a corporation organized under the laws of the
State of Oklahoma (the "Company"), hereby certifies that, for value received,
LAURUS MASTER FUND, LTD., or assigns (the "Holder"), is entitled, subject to the
terms set forth below, to purchase from the Company (as defined herein) from and
after the Issue Date of this Warrant and at any time or from time to time before
5:00 p.m., New York time, through the close of business June 28, 2011 (the
"Expiration Date"), up to 2,272,727 fully paid and nonassessable shares of
Common Stock (as hereinafter defined), $0.0001 par value per share, at the
applicable Exercise Price per share (as defined below). The number and character
of such shares of Common Stock and the applicable Exercise Price per share are
subject to adjustment as provided herein.

     As used herein the following terms, unless the context otherwise requires,
have the following respective meanings:

     (a)  The term "Company" shall include AMS Health Sciences, Inc. and any
          person or entity which shall succeed, or assume the obligations of,
          AMS Health Sciences, Inc. hereunder.

     (b)  The term "Common Stock" includes (i) the Company's Common Stock, par
          value $0.0001 per share; and (ii) any other securities into which or
          for which any of the securities described in the preceding clause (i)
          may be converted or exchanged pursuant to a plan of recapitalization,
          reorganization, merger, sale of assets or otherwise.

     (c)  The term "Other Securities" refers to any stock (other than Common
          Stock) and other securities of the Company or any other person
          (corporate or otherwise) which the holder of the Warrant at any time
          shall be entitled to receive, or shall have received, on the exercise
          of the Warrant, in lieu of or in addition to Common Stock, or which at
          any time shall be issuable or shall have been issued in exchange for
          or in replacement of Common Stock or Other Securities pursuant to
          Section 4 or otherwise.

     (d)  The "Exercise Price" applicable under this Warrant shall be as
          follows: (i) a price of $0.53;

     1. Exercise of Warrant.

          1.1. Number of Shares Issuable upon Exercise. From and after the date
     hereof through and including the Expiration Date, the Holder shall be
     entitled to receive, upon exercise of this Warrant in whole or in part, by
     delivery of an original or fax copy of an exercise notice in the form
     attached hereto as Exhibit A (the "Exercise Notice"), shares of Common
     Stock of the Company, subject to adjustment pursuant to Section 4.

          1.2. Company Acknowledgment. The Company will, at the time of the
     exercise of this Warrant, upon the request of the holder hereof acknowledge
     in writing its continuing obligation to afford to such holder any rights to
     which such holder shall continue to be entitled after such exercise in
     accordance with the provisions of this Warrant. If the holder shall fail to
     make any such request, such failure shall not affect the continuing
     obligation of the Company to afford to such holder any such rights.

          1.3. Trustee for Warrant Holders. In the event that a bank or trust
     company shall have been appointed as trustee for the holders of this
     Warrant pursuant to Subsection 3.2, such bank or trust company shall have
     all the powers and duties of a warrant agent (as hereinafter described) and
     shall accept, in its own name for the account of the Company or such
     successor person as may be entitled thereto, all amounts otherwise payable
     to the Company or such successor, as the case may be, on exercise of this
     Warrant pursuant to this Section 1.

     2. Procedure for Exercise.

          2.1. Delivery of Stock Certificates, Etc., on Exercise. The Company
     agrees that the shares of Common Stock purchased upon exercise of this
     Warrant shall be deemed to be issued to the Holder as the record owner of
     such shares as of the close of business on the date on which this Warrant
     shall have been surrendered and payment made for such shares in accordance
     herewith. As soon as practicable after the exercise of this Warrant in full
     or in part, and in any event within three (3) business days thereafter, the
     Company at its expense (including the payment by it of any applicable issue
     taxes) will cause to be issued in the name of and delivered to the Holder,
     or as such Holder (upon payment by such Holder of any applicable transfer
     taxes) may direct in compliance with applicable securities laws, a
     certificate or certificates for the number of duly and validly issued,
     fully paid and nonassessable shares of Common Stock (or Other Securities)
     to which such Holder shall be entitled on such exercise.,

          2.2. Exercise. (a) Payment may be made in cash or by certified or
     official bank check payable to the order of the Company equal to the
     applicable aggregate Exercise Price for the number of Common Shares
     specified in such Exercise Notice (as such exercise number shall be
     adjusted to reflect any adjustment in the total number of shares of Common
     Stock issuable to the Holder per the terms of this Warrant) and the Holder
     shall thereupon be entitled to receive the number of duly authorized,
     validly issued, fully-paid and non-assessable shares of Common Stock (or
     Other Securities) determined as provided herein.

     3. Effect of Reorganization, Etc.; Adjustment of Exercise Price.

          3.1. Reorganization, Consolidation, Merger, Etc. In case at any time
     or from time to time, the Company shall (a) effect a reorganization, (b)
     consolidate with or merge into any other person, or (c) transfer all or
     substantially all of its properties or assets to any other person under any
     plan or arrangement contemplating the dissolution of the Company, then, in
     each such case, as a condition to the consummation of such a transaction,
     proper and adequate provision shall be made by the Company whereby the
     Holder, on the exercise hereof as provided in Section 1 at any time after
     the consummation of such reorganization, consolidation or merger or the
     effective date of such dissolution, as the case may be, shall receive, in
     lieu of the Common Stock (or Other Securities) issuable on such exercise
     prior to such consummation or such effective date, the stock and other
     securities and property (including cash) to which such Holder would have
     been entitled upon such consummation or in connection with such
     dissolution, as the case may be, if such Holder had so exercised this
     Warrant, immediately prior thereto, all subject to further adjustment
     thereafter as provided in Section 4.

          3.2. Dissolution. In the event of any dissolution of the Company
     following the transfer of all or substantially all of its properties or
     assets, the Company, concurrently with any distributions made to holders of
     its Common Stock, shall at its expense deliver or cause to be delivered to
     the Holder the stock and other securities and property (including cash,
     where applicable) receivable by the Holder pursuant to Section 3.1, or, if
     the Holder shall so instruct the Company, to a bank or trust company
     specified by the Holder and having its principal office in New York, NY as
     trustee for the Holder (the "Trustee").

          3.3. Continuation of Terms. Upon any reorganization, consolidation,
     merger or transfer (and any dissolution following any transfer) referred to
     in this Section 3, this Warrant shall continue in full force and effect and
     the terms hereof shall be applicable to the shares of stock and other
     securities and property receivable on the exercise of this Warrant after
     the consummation of such reorganization, consolidation or merger or the
     effective date of dissolution following any such transfer, as the case may
     be, and shall be binding upon the issuer of any such stock or other
     securities, including, in the case of any such transfer, the person
     acquiring all or substantially all of the properties or assets of the
     Company, whether or not such person shall have expressly assumed the terms
     of this Warrant as provided in Section 4. In the event this Warrant does
     not continue in full force and effect after the consummation of the
     transactions described in this Section 3, then the Company's securities and
     property (including cash, where applicable) receivable by the Holder will
     be delivered to the Holder or the Trustee as contemplated by Section 3.2.

     4. Extraordinary Events Regarding Common Stock. In the event that the
Company shall (a) issue additional shares of the Common Stock as a dividend or
other distribution on outstanding Common Stock or any preferred stock issued by
the Company (b) subdivide its outstanding shares of Common Stock, or (c) combine
its outstanding shares of the Common Stock into a smaller number of shares of
the Common Stock, then, in each such event, the Exercise Price shall,
simultaneously with the happening of such event, be adjusted by multiplying the
then Exercise Price by a fraction, the numerator of which shall be the number of
shares of Common Stock outstanding immediately prior to such event and the
denominator of which shall be the number of shares of Common Stock outstanding
immediately after such event, and the product so obtained shall thereafter be
the Exercise Price then in effect. The Exercise Price, as so adjusted, shall be
readjusted in the same manner upon the happening of any successive event or
events described herein in this Section 4. The number of shares of Common Stock
that the Holder shall thereafter, on the exercise hereof as provided in Section
1, be entitled to receive shall be adjusted to a number determined by
multiplying the number of shares of Common Stock that would otherwise (but for
the provisions of this Section 4) be issuable on such exercise by a fraction of
which (a) the numerator is the Exercise Price that would otherwise (but for the
provisions of this Section 4) be in effect, and (b) the denominator is the
Exercise Price in effect on the date of such exercise (taking into account the
provisions of this Section 4). Notwithstanding the foregoing, in no event shall
the Exercise Price be less than the par value of the Common Stock.

     5. Certificate as to Adjustments. In each case of any adjustment or
readjustment in the shares of Common Stock (or Other Securities) issuable on the
exercise of this Warrant, the Company at its expense will promptly cause its
Chief Financial Officer or other appropriate designee to compute such adjustment
or readjustment in accordance with the terms of this Warrant and prepare a
certificate setting forth such adjustment or readjustment and showing in detail
the facts upon which such adjustment or readjustment is based, including a
statement of (a) the consideration received or receivable by the Company for any
additional shares of Common Stock (or Other Securities) issued or sold or deemed
to have been issued or sold, (b) the number of shares of Common Stock (or Other
Securities) outstanding or deemed to be outstanding, and (c) the Exercise Price
and the number of shares of Common Stock to be received upon exercise of this
Warrant, in effect immediately prior to such adjustment or readjustment and as
adjusted or readjusted as provided in this Warrant. The Company will forthwith
mail a copy of each such certificate to the Holder and any Warrant agent of the
Company (appointed pursuant to Section 11 hereof).

     6. Reservation of Stock, Etc., Issuable on Exercise of Warrant. The Company
will at all times reserve and keep available, solely for issuance and delivery
on the exercise of this Warrant, shares of Common Stock (or Other Securities)
from time to time issuable on the exercise of this Warrant.

     7. Assignment; Exchange of Warrant. Subject to compliance with applicable
securities laws, this Warrant, and the rights evidenced hereby, may be
transferred by any registered holder hereof (a "Transferor") in whole or in
part. On the surrender for exchange of this Warrant, with the Transferor's
endorsement in the form of Exhibit B attached hereto (the "Transferor
Endorsement Form") and together with evidence reasonably satisfactory to the
Company demonstrating compliance with applicable securities laws, which shall
include, without limitation, the provision of a legal opinion from the
Transferor's counsel (at the Company's expense) that such transfer is exempt
from the registration requirements of applicable securities laws, the Company at
its expense (but with payment by the Transferor of any applicable transfer
taxes) will issue and deliver to or on the order of the Transferor thereof a new
Warrant of like tenor, in the name of the Transferor and/or the transferee(s)
specified in such Transferor Endorsement Form (each a "Transferee"), calling in
the aggregate on the face or faces thereof for the number of shares of Common
Stock called for on the face or faces of the Warrant so surrendered by the
Transferor.

     8. Replacement of Warrant. On receipt of evidence reasonably satisfactory
to the Company of the loss, theft, destruction or mutilation of this Warrant
and, in the case of any such loss, theft or destruction of this Warrant, on
delivery of an indemnity agreement or security reasonably satisfactory in form
and amount to the Company or, in the case of any such mutilation, on surrender
and cancellation of this Warrant, the Company at its expense will execute and
deliver, in lieu thereof, a new Warrant of like tenor.

     9. Registration Rights. The Holder has been granted certain registration
rights by the Company. These registration rights are set forth in a Registration
Rights Agreement entered into by the Company and Holder dated as of the date
hereof, as the same may be amended, modified and/or supplemented from time to
time.

     10. Maximum Exercise. Notwithstanding anything herein to the contrary, in
no event shall the Holder be entitled to exercise any portion of this Warrant in
excess of that portion of this Warrant upon exercise of which the sum of (1) the
number of shares of Common Stock beneficially owned by the Holder and its
Affiliates (other than shares of Common Stock which may be deemed beneficially
owned through the ownership of the unexercised portion of the Warrant or the
unexercised or unconverted portion of any other security of the Holder subject
to a limitation on conversion analogous to the limitations contained herein) and
(2) the number of shares of Common Stock issuable upon the exercise of the
portion of this Warrant with respect to which the determination of this proviso
is being made, would result in beneficial ownership by the Holder and its
Affiliates of any amount greater than 4.99% of the then outstanding shares of
Common Stock (whether or not, at the time of such exercise, the Holder and its
Affiliates beneficially own more than 4.99% of the then outstanding shares of
Common Stock). As used herein, the term "Affiliate" means any person or entity
that, directly or indirectly through one or more intermediaries, controls or is
controlled by or is under common control with a person or entity, as such terms
are used in and construed under Rule 144 under the Securities Act. For purposes
of the proviso to the second preceding sentence, beneficial ownership shall be
determined in accordance with Section 13(d) of the Securities Exchange Act of
1934, as amended, and Regulations 13D-G thereunder, except as otherwise provided
in clause (1) of such proviso. The limitations set forth herein (x) may be
waived by the Holder upon provision of no less than sixty-one (61) days prior
notice to the Company and (y) shall automatically become null and void following
notice to the Company upon the occurrence and during the continuance of an Event
of Default (as defined in the Note referred to in the Purchase Agreement dated
as of the date hereof among the Holder and the Company (as amended, modified,
restated and/or supplemented from time to time, the "Purchase Agreement")).

     11. Warrant Agent. The Company may, by written notice to the each Holder of
the Warrant, appoint an agent for the purpose of issuing Common Stock (or Other
Securities) on the exercise of this Warrant pursuant to Section 1, exchanging
this Warrant pursuant to Section 7, and replacing this Warrant pursuant to
Section 8, or any of the foregoing, and thereafter any such issuance, exchange
or replacement, as the case may be, shall be made at such office by such agent.

     12. Transfer on the Company's Books. Until this Warrant is transferred on
the books of the Company, the Company may treat the registered holder hereof as
the absolute owner hereof for all purposes, notwithstanding any notice to the
contrary.

     13. Notices, Etc. All notices and other communications from the Company to
the Holder shall be mailed by first class registered or certified mail, postage
prepaid, at such address as may have been furnished to the Company in writing by
such Holder or, until any such Holder furnishes to the Company an address, then
to, and at the address of, the last Holder who has so furnished an address to
the Company.

     14. Miscellaneous. This Warrant and any term hereof may be changed, waived,
discharged or terminated only by an instrument in writing signed by the party
against which enforcement of such change, waiver, discharge or termination is
sought. THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE
LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAWS.
ANY ACTION BROUGHT CONCERNING THE TRANSACTIONS CONTEMPLATED BY THIS WARRANT
SHALL BE BROUGHT ONLY IN THE STATE COURTS OF NEW YORK OR IN THE FEDERAL COURTS
LOCATED IN THE STATE OF NEW YORK; PROVIDED, HOWEVER, THAT THE HOLDER MAY CHOOSE
TO WAIVE THIS PROVISION AND BRING AN ACTION OUTSIDE THE STATE OF NEW YORK. The
individuals executing this Warrant on behalf of the Company agree to submit to
the jurisdiction of such courts and waive trial by jury. The prevailing party
shall be entitled to recover from the other party its reasonable attorneys' fees
and costs. In the event that any provision of this Warrant is invalid or
unenforceable under any applicable statute or rule of law, then such provision
shall be deemed inoperative to the extent that it may conflict therewith and
shall be deemed modified to conform with such statute or rule of law. Any such
provision which may prove invalid or unenforceable under any law shall not
affect the validity or enforceability of any other provision of this Warrant.
The headings in this Warrant are for purposes of reference only, and shall not
limit or otherwise affect any of the terms hereof. The invalidity or
unenforceability of any provision hereof shall in no way affect the validity or
enforceability of any other provision hereof. The Company acknowledges that
legal counsel participated in the preparation of this Warrant and, therefore,
stipulates that the rule of construction that ambiguities are to be resolved
against the drafting party shall not be applied in the interpretation of this
Warrant to favor any party against the other party.

                   [BALANCE OF PAGE INTENTIONALLY LEFT BLANK;
                             SIGNATURE PAGE FOLLOWS]

<PAGE>

     IN WITNESS WHEREOF, the Company has executed this Warrant as of the date
first written above.

                                     AMS HEALTH SCIENCES, INC.

WITNESS:
                                     By:   /s/Jerry W. Grizzle
/s/Robin L. Jacob                    Name:  Jerry W. Grizzle
Robin L. Jacob                       Title: Chairman, President & CEO

<PAGE>

                                    Exhibit A

                              FORM OF SUBSCRIPTION
                   (To Be Signed Only On Exercise Of Warrant)

    TO:  AMS Health Sciences, Inc.

         Attention:        Chief Financial Officer

     The undersigned, pursuant to the provisions set forth in the attached
Warrant (No.____), hereby irrevocably elects to purchase (check applicable box):

_______     ________ shares of the Common Stock covered by such Warrant; or

     The undersigned herewith makes payment of the full Exercise Price for such
shares at the price per share provided for in such Warrant, which is
$___________. Such payment takes the form of (check applicable box or boxes):

_______    $__________ in lawful money of the United States; and/or

     The undersigned requests that the certificates for such shares be issued in
the name of, and delivered to ______________________________________________
whose address is _____________________________________________________________.

     The undersigned represents and warrants that all offers and sales by the
undersigned of the securities issuable upon exercise of the within Warrant shall
be made pursuant to registration of the Common Stock under the Securities Act of
1933, as amended (the "Securities Act") or pursuant to an exemption from
registration under the Securities Act.

Dated:
                                    (Signature must conform to name of holder as
                                    specified on the face of the Warrant)

                                    Address:

<PAGE>
                                    Exhibit B

                         FORM OF TRANSFEROR ENDORSEMENT
                   (To Be Signed Only On Transfer Of Warrant)

         For value received, the undersigned hereby sells, assigns, and
transfers unto the person(s) named below under the heading "Transferees" the
right represented by the within Warrant to purchase the percentage and number of
shares of Common Stock of AMS Health Sciences, Inc. into which the within
Warrant relates specified under the headings "Percentage Transferred" and
"Number Transferred," respectively, opposite the name(s) of such person(s) and
appoints each such person Attorney to transfer its respective right on the books
of AMS Health Sciences, Inc. with full power of substitution in the premises.

                                             Percentage              Number
Transferees           Address               Transferred           Transferred
-----------           -------               -----------           -----------

Dated:
                                    (Signature must conform to name of holder as
                                    specified on the face of the Warrant)

                                    Address:

                                    SIGNED IN THE PRESENCE OF:

                                                (Name)
ACCEPTED AND AGREED:
[TRANSFEREE]

     (Name)EXHIBIT 10.16

                          REGISTRATION RIGHTS AGREEMENT

     This Registration Rights Agreement (this "Agreement") is made and entered
into as of June 28, 2006, by and between AMS Health Sciences, Inc., an Oklahoma
corporation (the "Company"), and Laurus Master Fund, Ltd. (the "Purchaser").

     This Agreement is made pursuant to the Securities Purchase Agreement, dated
as of the date hereof, by and between the Purchaser and the Company (as amended,
modified or supplemented from time to time, the "Securities Purchase
Agreement"), and pursuant to the Note and the Warrants referred to therein.

     The Company and the Purchaser hereby agree as follows:

     1. Definitions. Capitalized terms used and not otherwise defined herein
that are defined in the Securities Purchase Agreement shall have the meanings
given such terms in the Securities Purchase Agreement. As used in this
Agreement, the following terms shall have the following meanings:

          "Commission" means the Securities and Exchange Commission.

          "Common Stock" means shares of the Company's common stock, par value
$0.0001 per share.

          "Effectiveness Date" means (i) with respect to the initial
Registration Statement required to be filed hereunder, a date no later than one
hundred eighty (180) days following the date hereof and (ii) with respect to
each additional Registration Statement required to be filed hereunder, a date no
later than thirty (30) days following the applicable Filing Date.

          "Effectiveness Period" has the meaning set forth in Section 2(a).

          "Exchange Act" means the Securities Exchange Act of 1934, as amended,
and any successor statute.

          "Filing Date" means, with respect to (i) the Registration Statement
required to be filed hereunder in respect of the shares of Common Stock issuable
upon conversion of the Note, a date no later than sixty (60) days following the
date hereof, (ii) the shares of Common Stock issuable upon exercise of any
Warrant, the date which is thirty (30) days after the date of the issuance of
such Warrant, and (iii) the shares of Common Stock issuable to the Holder as a
result of adjustments to the Fixed Conversion Price or Exercise Price, as the
case may be, made pursuant to the Note or the Warrant or otherwise, thirty (30)
days after the occurrence such event or the date of the adjustment of the Fixed
Conversion Price or Exercise Price, as the case may be.

          "Holder" or "Holders" means the Purchaser or any of its affiliates or
transferees to the extent any of them hold Registrable Securities, other than
those purchasing Registrable Securities in a market transaction.

          "Indemnified Party" has the meaning set forth in Section 5(c).

          "Indemnifying Party" has the meaning set forth in Section 5(c).

          "Note" has the meaning set forth in the Securities Purchase Agreement.

          "Proceeding" means an action, claim, suit, investigation or proceeding
(including, without limitation, an investigation or partial proceeding, such as
a deposition), whether commenced or threatened.

          "Prospectus" means the prospectus included in the Registration
Statement (including, without limitation, a prospectus that includes any
information previously omitted from a prospectus filed as part of an effective
registration statement in reliance upon Rules 430A, 430B or 430C promulgated
under the Securities Act), as amended or supplemented by any prospectus
supplement, with respect to the terms of the offering of any portion of the
Registrable Securities covered by the Registration Statement, and all other
amendments and supplements to the Prospectus, including post-effective
amendments, and all material incorporated by reference or deemed to be
incorporated by reference in such Prospectus.

          "Registrable Securities" means the shares of Common Stock issued upon
the conversion of the Note and issuable upon exercise of the Warrants.

          "Registration Statement" means each registration statement required to
be filed hereunder, including the Prospectus therein, amendments and supplements
to such registration statement or Prospectus, including pre- and post-effective
amendments, all exhibits thereto, and all material incorporated by reference or
deemed to be incorporated by reference in such registration statement.

          "Rule 144" means Rule 144 promulgated by the Commission pursuant to
the Securities Act, as such Rule may be amended from time to time, or any
similar rule or regulation hereafter adopted by the Commission having
substantially the same effect as such Rule.

          "Rule 415" means Rule 415 promulgated by the Commission pursuant to
the Securities Act, as such Rule may be amended from time to time, or any
similar rule or regulation hereafter adopted by the Commission having
substantially the same effect as such Rule.

          "Securities Act" means the Securities Act of 1933, as amended, and any
successor statute.

          "Securities Purchase Agreement" has the meaning given to such term in
the Preamble hereto.

          "Trading Market" means any of the NASD Over The Counter Bulletin
Board, NASDAQ Capital Market, the NASDAQ National Markets System, the American
Stock Exchange or the New York Stock Exchange.

          "Warrants" means the Common Stock purchase warrants issued in
connection with the Securities Purchase Agreement, whether on the date hereof or
thereafter.

     2. Registration.

          (a) On or prior to the Filing Date the Company shall prepare and file
     with the Commission a Registration Statement covering the Registrable
     Securities for a selling stockholder resale offering to be made on a
     continuous basis pursuant to Rule 415. The Registration Statement shall be
     on Form S-3 (except if the Company is not then eligible to register for
     resale the Registrable Securities on Form S-3, in which case such
     registration shall be on another appropriate form in accordance herewith).
     The Company shall cause each Registration Statement to become effective and
     remain effective as provided herein. The Company shall use its best efforts
     to cause each Registration Statement to be declared effective under the
     Securities Act as promptly as possible after the filing thereof, but in any
     event no later than the Effectiveness Date. The Company shall use its
     reasonable commercial efforts to keep each Registration Statement
     continuously effective under the Securities Act until the date which is the
     earlier date of when (i) all Registrable Securities have been sold or (ii)
     all Registrable Securities covered by such Registration Statement may be
     sold immediately without registration under the Securities Act and without
     volume restrictions pursuant to Rule 144, as determined by the counsel to
     the Company pursuant to a written opinion letter to such effect, addressed
     and acceptable to the Company's transfer agent and the affected Holders
     (the "Effectiveness Period").

          (b) Within three business days of the Effectiveness Date, the Company
     shall cause its counsel to issue a blanket opinion in the form attached
     hereto as Exhibit A, to the transfer agent stating that the shares are
     subject to an effective registration statement and can be reissued free of
     restrictive legend upon notice of a sale by the Purchaser and confirmation
     by the Purchaser that it has complied with the prospectus delivery
     requirements, provided that the Company has not advised the transfer agent
     orally or in writing that the opinion has been withdrawn. Copies of the
     blanket opinion required by this Section 2(b) shall be delivered to the
     Purchaser within the time frame set forth above.

     3. Registration Procedures. If and whenever the Company is required by the
provisions hereof to effect the registration of any Registrable Securities under
the Securities Act, the Company will, as expeditiously as possible:

          (a) prepare and file with the Commission a Registration Statement with
     respect to such Registrable Securities, respond as promptly as possible to
     any comments received from the Commission, and use its best efforts to
     cause the Registration Statement to become and remain effective for the
     Effectiveness Period with respect thereto, and promptly provide to the
     Purchaser copies of all filings and Commission letters of comment relating
     thereto;

          (b) prepare and file with the Commission such amendments and
     supplements to the Registration Statement and the Prospectus used in
     connection therewith as may be necessary to comply with the provisions of
     the Securities Act with respect to the disposition of all Registrable
     Securities covered by such Registration Statement and to keep such
     Registration Statement effective until the expiration of the Effectiveness
     Period applicable to such Registration Statement;

          (c) furnish to the Purchaser such number of copies of the Registration
     Statement and the Prospectus included therein (including each preliminary
     Prospectus) as the Purchaser reasonably may request to facilitate the
     public sale or disposition of the Registrable Securities covered by the
     Registration Statement;

          (d) use its best efforts to register or qualify the Purchaser's
     Registrable Securities covered by such Registration Statement under the
     securities or "blue sky" laws of such jurisdictions within the United
     States as the Purchaser may reasonably request, provided, however, that the
     Company shall not for any such purpose be required to qualify generally to
     transact business as a foreign corporation in any jurisdiction where it is
     not so qualified or to consent to general service of process in any such
     jurisdiction;

          (e) list the Registrable Securities covered by such Registration
     Statement with any securities exchange on which the Common Stock of the
     Company is then listed;

          (f) immediately notify the Purchaser at any time when a Prospectus
     relating thereto is required to be delivered under the Securities Act, of
     the happening of any event of which the Company has knowledge as a result
     of which the Prospectus contained in such Registration Statement, as then
     in effect, includes an untrue statement of a material fact or omits to
     state a material fact required to be stated therein or necessary to make
     the statements therein not misleading in light of the circumstances then
     existing; and

          (g) make available for inspection by the Purchaser and any attorney,
     accountant or other agent retained by the Purchaser, all publicly
     available, non-confidential financial and other records, pertinent
     corporate documents and properties of the Company, and cause the Company's
     officers, directors and employees to supply all publicly available,
     non-confidential information reasonably requested by the attorney,
     accountant or agent of the Purchaser.

     4. Registration Expenses. All expenses relating to the Company's compliance
with Sections 2 and 3 hereof, including, without limitation, all registration
and filing fees, printing expenses, fees and disbursements of counsel and
independent public accountants for the Company, fees and expenses (including
reasonable counsel fees) incurred in connection with complying with state
securities or "blue sky" laws, fees of the NASD, transfer taxes, fees of
transfer agents and registrars, fees of, and disbursements incurred by, one
counsel for the Holders, are called "Registration Expenses". All selling
commissions applicable to the sale of Registrable Securities, including any fees
and disbursements of any special counsel to the Holders beyond those included in
Registration Expenses, are called "Selling Expenses." The Company shall only be
responsible for all Registration Expenses.

     5. Indemnification.

          (a) In the event of a registration of any Registrable Securities under
     the Securities Act pursuant to this Agreement, the Company will indemnify
     and hold harmless the Purchaser, and its officers, directors and each other
     person, if any, who controls the Purchaser within the meaning of the
     Securities Act, against any losses, claims, damages or liabilities, joint
     or several, to which the Purchaser, or such persons may become subject
     under the Securities Act or otherwise, insofar as such losses, claims,
     damages or liabilities (or actions in respect thereof) arise out of or are
     based upon any untrue statement or alleged untrue statement of any material
     fact contained in any Registration Statement under which such Registrable
     Securities were registered under the Securities Act pursuant to this
     Agreement, any preliminary Prospectus or final Prospectus contained
     therein, or any amendment or supplement thereof, or arise out of or are
     based upon the omission or alleged omission to state therein a material
     fact required to be stated therein or necessary to make the statements
     therein not misleading, and will reimburse the Purchaser, and each such
     person for any reasonable legal or other expenses incurred by them in
     connection with investigating or defending any such loss, claim, damage,
     liability or action; provided, however, that the Company will not be liable
     in any such case if and to the extent that any such loss, claim, damage or
     liability arises out of or is based upon an untrue statement or alleged
     untrue statement or omission or alleged omission so made in conformity with
     information furnished by or on behalf of the Purchaser or any such person
     in writing specifically for use in any such document.

          (b) In the event of a registration of the Registrable Securities under
     the Securities Act pursuant to this Agreement, the Purchaser will indemnify
     and hold harmless the Company, and its officers, directors and each other
     person, if any, who controls the Company within the meaning of the
     Securities Act, against all losses, claims, damages or liabilities, joint
     or several, to which the Company or such persons may become subject under
     the Securities Act or otherwise, insofar as such losses, claims, damages or
     liabilities (or actions in respect thereof) arise out of or are based upon
     any untrue statement or alleged untrue statement of any material fact which
     was furnished in writing by the Purchaser to the Company expressly for use
     in (and such information is contained in) the Registration Statement under
     which such Registrable Securities were registered under the Securities Act
     pursuant to this Agreement, any preliminary Prospectus or final Prospectus
     contained therein, or any amendment or supplement thereof, or arise out of
     or are based upon the omission or alleged omission to state therein a
     material fact required to be stated therein or necessary to make the
     statements therein not misleading, and will reimburse the Company and each
     such person for any reasonable legal or other expenses incurred by them in
     connection with investigating or defending any such loss, claim, damage,
     liability or action, provided, however, that the Purchaser will be liable
     in any such case if and only to the extent that any such loss, claim,
     damage or liability arises out of or is based upon an untrue statement or
     alleged untrue statement or omission or alleged omission so made in
     conformity with information furnished in writing to the Company by or on
     behalf of the Purchaser specifically for use in any such document.
     Notwithstanding the provisions of this paragraph, the Purchaser shall not
     be required to indemnify any person or entity in excess of the amount of
     the aggregate net proceeds received by the Purchaser in respect of
     Registrable Securities in connection with any such registration under the
     Securities Act.

          (c) Promptly after receipt by a party entitled to claim
     indemnification hereunder (an "Indemnified Party") of notice of the
     commencement of any action, such Indemnified Party shall, if a claim for
     indemnification in respect thereof is to be made against a party hereto
     obligated to indemnify such Indemnified Party (an "Indemnifying Party"),
     notify the Indemnifying Party in writing thereof, but the omission so to
     notify the Indemnifying Party shall not relieve it from any liability which
     it may have to such Indemnified Party other than under this Section 5(c)
     and shall only relieve it from any liability which it may have to such
     Indemnified Party under this Section 5(c) if and to the extent the
     Indemnifying Party is prejudiced by such omission. In case any such action
     shall be brought against any Indemnified Party and it shall notify the
     Indemnifying Party of the commencement thereof, the Indemnifying Party
     shall be entitled to participate in and, to the extent it shall wish, to
     assume and undertake the defense thereof with counsel satisfactory to such
     Indemnified Party, and, after notice from the Indemnifying Party to such
     Indemnified Party of its election so to assume and undertake the defense
     thereof, the Indemnifying Party shall not be liable to such Indemnified
     Party under this Section 5(c) for any legal expenses subsequently incurred
     by such Indemnified Party in connection with the defense thereof; if the
     Indemnified Party retains its own counsel, then the Indemnified Party shall
     pay all fees, costs and expenses of such counsel, provided, however, that,
     if the defendants in any such action include both the Indemnified Party and
     the Indemnifying Party and the Indemnified Party shall have reasonably
     concluded that there may be reasonable defenses available to it which are
     different from or additional to those available to the Indemnifying Party
     or if the interests of the Indemnified Party reasonably may be deemed to
     conflict with the interests of the Indemnifying Party, the Indemnified
     Party shall have the right to select one separate counsel and to assume
     such legal defenses and otherwise to participate in the defense of such
     action, with the reasonable expenses and fees of such separate counsel and
     other expenses related to such participation to be reimbursed by the
     Indemnifying Party as incurred.

          (d) In order to provide for just and equitable contribution in the
     event of joint liability under the Securities Act in any case in which
     either (i) the Purchaser, or any officer, director or controlling person of
     the Purchaser, makes a claim for indemnification pursuant to this Section 5
     but it is judicially determined (by the entry of a final judgment or decree
     by a court of competent jurisdiction and the expiration of time to appeal
     or the denial of the last right of appeal) that such indemnification may
     not be enforced in such case notwithstanding the fact that this Section 5
     provides for indemnification in such case, or (ii) contribution under the
     Securities Act may be required on the part of the Purchaser or such
     officer, director or controlling person of the Purchaser in circumstances
     for which indemnification is provided under this Section 5; then, and in
     each such case, the Company and the Purchaser will contribute to the
     aggregate losses, claims, damages or liabilities to which they may be
     subject (after contribution from others) in such proportion so that the
     Purchaser is responsible only for the portion represented by the percentage
     that the public offering price of its securities offered by the
     Registration Statement bears to the public offering price of all securities
     offered by such Registration Statement, provided, however, that, in any
     such case, (A) the Purchaser will not be required to contribute any amount
     in excess of the public offering price of all such securities offered by it
     pursuant to such Registration Statement; and (B) no person or entity guilty
     of fraudulent misrepresentation (within the meaning of Section 10(f) of the
     Act) will be entitled to contribution from any person or entity who was not
     guilty of such fraudulent misrepresentation.

     6. Representations and Warranties.

          (a) The Common Stock is registered pursuant to Section 12(b) or 12(g)
     of the Exchange Act and, except with respect to certain matters which the
     Company has disclosed to the Purchaser on Schedule 4.21 to the Securities
     Purchase Agreement, the Company has timely filed all proxy statements,
     reports, schedules, forms, statements and other documents required to be
     filed by it under the Exchange Act. The Company has filed (i) its Annual
     Report on Form 10-KSB for its fiscal year ended December 31, 2005 and (ii)
     its Quarterly Report on Form 10-QSB for the fiscal quarter ended March 31,
     2006 (collectively, the "SEC Reports"). Each SEC Report was, at the time of
     its filing, in substantial compliance with the requirements of its
     respective form and none of the SEC Reports, nor the financial statements
     (and the notes thereto) included in the SEC Reports, as of their respective
     filing dates, contained any untrue statement of a material fact or omitted
     to state a material fact required to be stated therein or necessary to make
     the statements therein, in light of the circumstances under which they were
     made, not misleading. The financial statements of the Company included in
     the SEC Reports comply as to form in all material respects with applicable
     accounting requirements and the published rules and regulations of the
     Commission or other applicable rules and regulations with respect thereto.
     Such financial statements have been prepared in accordance with generally
     accepted accounting principles ("GAAP") applied on a consistent basis
     during the periods involved (except (i) as may be otherwise indicated in
     such financial statements or the notes thereto or (ii) in the case of
     unaudited interim statements, to the extent they may not include footnotes
     or may be condensed) and fairly present in all material respects the
     financial condition, the results of operations and the cash flows of the
     Company and its subsidiaries, on a consolidated basis, as of, and for, the
     periods presented in each such SEC Report.

          (b) Except otherwise set forth in the Company's SEC reports and on
     Schedule 6(b), the Common Stock is listed for trading on the American Stock
     Exchange and satisfies all requirements for the continuation of such
     listing, and the Company shall do all things necessary for the continuation
     of such listing. Except as set forth on Schedule 6(b), the Company has not
     received any notice that its Common Stock will be delisted from the
     American Stock Exchange (except for prior notices which have been fully
     remedied) or that the Common Stock dos not meet all requirements for the
     continuation of such listing.

          (c) Neither the Company, nor any of its affiliates, nor any person
     acting on its or their behalf, has directly or indirectly made any offers
     or sales of any security or solicited any offers to buy any security under
     circumstances that would cause the offering of the Securities pursuant to
     the Securities Purchase Agreement to be integrated with prior offerings by
     the Company for purposes of the Securities Act which would prevent the
     Company from selling the Common Stock pursuant to Rule 506 under the
     Securities Act, or any applicable exchange-related stockholder approval
     provisions, nor will the Company or any of its affiliates or subsidiaries
     take any action or steps that would cause the offering of the Securities to
     be integrated with other offerings.

          (d) The Warrants, the Note and the shares of Common Stock which the
     Purchaser may acquire pursuant to the Warrants and the Note are all
     restricted securities under the Securities Act as of the date of this
     Agreement. The Company will not issue any stop transfer order or other
     order impeding the sale and delivery of any of the Registrable Securities
     at such time as such Registrable Securities are registered for public sale
     or an exemption from registration is available, except as required by
     federal or state securities laws.

          (e) The Company understands the nature of the Registrable Securities
     issuable upon the conversion of the Note and the exercise of the Warrant
     and recognizes that the issuance of such Registrable Securities may have a
     potential dilutive effect. The Company specifically acknowledges that its
     obligation to issue the Registrable Securities is binding upon the Company
     and enforceable regardless of the dilution such issuance may have on the
     ownership interests of other shareholders of the Company.

          (f) Except for agreements made in the ordinary course of business,
     there is no agreement that has not been filed with the Commission as an
     exhibit to a registration statement or to a form required to be filed by
     the Company under the Exchange Act, the breach of which could reasonably be
     expected to have a material and adverse effect on the Company and its
     subsidiaries, or would prohibit or otherwise interfere with the ability of
     the Company to enter into and perform any of its obligations under this
     Agreement in any material respect.

          (g) The Company will at all times have authorized and reserved a
     sufficient number of shares of Common Stock for the full conversion of the
     Note and exercise of the Warrants.

     7. Miscellaneous.

          (a) Remedies. In the event of a breach by the Company or by a Holder,
     of any of their respective obligations under this Agreement, each Holder or
     the Company, as the case may be, in addition to being entitled to exercise
     all rights granted by law and under this Agreement, including recovery of
     damages, will be entitled to specific performance of its rights under this
     Agreement.

          (b) No Piggyback on Registrations. Except as and to the extent
     specified in Schedule 7(b) hereto, neither the Company nor any of its
     security holders (other than the Holders in such capacity pursuant hereto)
     may include securities of the Company in any Registration Statement other
     than the Registrable Securities, and the Company shall not after the date
     hereof enter into any agreement providing any such right for inclusion of
     shares in the Registration Statement to any of its security holders. Except
     as and to the extent specified in Schedule 7(b) hereto, the Company has not
     previously entered into any agreement granting any registration rights with
     respect to any of its securities to any person or entity that have not been
     fully satisfied.

          (c) Compliance. Each Holder covenants and agrees that it will comply
     with the prospectus delivery requirements of the Securities Act as
     applicable to it in connection with sales of Registrable Securities
     pursuant to the Registration Statement.

          (d) Discontinued Disposition. Each Holder agrees by its acquisition of
     such Registrable Securities that, upon receipt of a notice from the Company
     of the occurrence of a Discontinuation Event (as defined below), such
     Holder will forthwith discontinue disposition of such Registrable
     Securities under the applicable Registration Statement until such Holder's
     receipt of the copies of the supplemented Prospectus and/or amended
     Registration Statement or until it is advised in writing (the "Advice") by
     the Company that the use of the applicable Prospectus may be resumed, and,
     in either case, has received copies of any additional or supplemental
     filings that are incorporated or deemed to be incorporated by reference in
     such Prospectus or Registration Statement. The Company may provide
     appropriate stop orders to enforce the provisions of this paragraph. For
     purposes of this Agreement, a "Discontinuation Event" shall mean (i) when
     the Commission notifies the Company whether there will be a "review" of
     such Registration Statement and whenever the Commission comments in writing
     on such Registration Statement (the Company shall provide true and complete
     copies thereof and all written responses thereto to each of the Holders);
     (ii) any request by the Commission or any other Federal or state
     governmental authority for amendments or supplements to such Registration
     Statement or Prospectus or for additional information; (iii) the issuance
     by the Commission of any stop order suspending the effectiveness of such
     Registration Statement covering any or all of the Registrable Securities or
     the initiation of any Proceedings for that purpose; (iv) the receipt by the
     Company of any notification with respect to the suspension of the
     qualification or exemption from qualification of any of the Registrable
     Securities for sale in any jurisdiction, or the initiation or threatening
     of any Proceeding for such purpose; and/or (v) the occurrence of any event
     or passage of time that makes the financial statements included in such
     Registration Statement ineligible for inclusion therein or any statement
     made in such Registration Statement or Prospectus or any document
     incorporated or deemed to be incorporated therein by reference untrue in
     any material respect or that requires any revisions to such Registration
     Statement, Prospectus or other documents so that, in the case of such
     Registration Statement or Prospectus, as the case may be, it will not
     contain any untrue statement of a material fact or omit to state any
     material fact required to be stated therein or necessary to make the
     statements therein, in light of the circumstances under which they were
     made, not misleading.

          (e) Piggy-Back Registrations. If at any time after the date hereof
     there is not an effective Registration Statement covering all of the
     Registrable Securities required to be covered hereunder and the Company
     shall determine to prepare and file with the Commission a registration
     statement relating to an offering for its own account or the account of
     others under the Securities Act of any of its equity securities, other than
     on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or
     their then equivalents relating to equity securities to be issued solely in
     connection with any acquisition of any entity or business or equity
     securities issuable in connection with stock option or other employee
     benefit plans or exchange offer, then the Company shall send to each Holder
     written notice of such determination and, if within fifteen (15) days after
     receipt of such notice, any such Holder shall so request in writing, the
     Company shall include in such registration statement all or any part of
     such Registrable Securities such Holder requests to be registered to the
     extent the Company may do so without violating registration rights of
     others which exist as of the date of this Agreement, subject to customary
     underwriter cutbacks applicable to all holders of registration rights and
     subject to obtaining any required consent of any selling stockholder(s) to
     such inclusion under such registration statement.

          (f) Amendments and Waivers. The provisions of this Agreement,
     including the provisions of this sentence, may not be amended, modified or
     supplemented, and waivers or consents to departures from the provisions
     hereof may not be given, unless the same shall be in writing and signed by
     the Company and the Holders of the then outstanding Registrable Securities.
     Notwithstanding the foregoing, a waiver or consent to depart from the
     provisions hereof with respect to a matter that relates exclusively to the
     rights of certain Holders and that does not directly or indirectly affect
     the rights of other Holders may be given by Holders of at least a majority
     of the Registrable Securities to which such waiver or consent relates;
     provided, however, that the provisions of this sentence may not be amended,
     modified, or supplemented except in accordance with the provisions of the
     immediately preceding sentence.

          (g) Notices. Any notice or request hereunder may be given to the
     Company or the Purchaser at the respective addresses set forth below or as
     may hereafter be specified in a notice designated as a change of address
     under this Section 7(g). Any notice or request hereunder shall be given by
     registered or certified mail, return receipt requested, hand delivery,
     overnight mail, Federal Express or other national overnight next day
     carrier (collectively, "Courier") or telecopy (confirmed by mail). Notices
     and requests shall be, in the case of those by hand delivery, deemed to
     have been given when delivered to any party to whom it is addressed, in the
     case of those by mail or overnight mail, deemed to have been given three
     (3) business days after the date when deposited in the mail or with the
     overnight mail carrier, in the case of a Courier, the next business day
     following timely delivery of the package with the Courier, and, in the case
     of a telecopy, when confirmed. The address for such notices and
     communications shall be as follows:

     If to the Company:        AMS Health Sciences, Inc.
                               711 NE39th
                               Oklahoma City, OK 73105

                               Attention:  Chief Financial Officer
                               Facsimile:  (405) 843-4935

                               with a copy to:

                               McAfee & Taft
                               10th Floor, 2 Leadership Square
                               Oklahoma City, OK 73102-7103

                               Attention:  David Ketelsleger
                               Facsimile:  (405) 228-7436

     If to a Purchaser:        To the address set forth under such Purchaser
                               name on the signature pages hereto.

     If to any other Person    To the address of such Holder as it appears in
     who is then the           the stock transfer books of the Company
     registered Holder:

or such other address as may be designated in writing hereafter in accordance
with this Section 7(g) by such Person.

          (h) Successors and Assigns. This Agreement shall inure to the benefit
     of and be binding upon the successors and permitted assigns of each of the
     parties and shall inure to the benefit of each Holder. The Company may not
     assign its rights or obligations hereunder without the prior written
     consent of each Holder. Each Holder may assign their respective rights
     hereunder in the manner and to the persons and entities as permitted under
     the Note and the Securities Purchase Agreement.

          (i) Execution and Counterparts. This Agreement may be executed in any
     number of counterparts, each of which when so executed shall be deemed to
     be an original and, all of which taken together shall constitute one and
     the same agreement. In the event that any signature is delivered by
     facsimile transmission, such signature shall create a valid binding
     obligation of the party executing (or on whose behalf such signature is
     executed) the same with the same force and effect as if such facsimile
     signature were the original thereof.

          (j) Governing Law, Jurisdiction and Waiver of Jury Trial. THIS
     AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE
     WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND
     PERFORMED IN SUCH STATE, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW.
     The Company hereby consents and agrees that the state or federal courts
     located in the County of New York, State of New York shall have exclusion
     jurisdiction to hear and determine any Proceeding between the Company, on
     the one hand, and the Purchaser, on the other hand, pertaining to this
     Agreement or to any matter arising out of or related to this Agreement;
     provided, that the Purchaser and the Company acknowledge that any appeals
     from those courts may have to be heard by a court located outside of the
     County of New York, State of New York, and further provided, that nothing
     in this Agreement shall be deemed or operate to preclude the Purchaser from
     bringing a Proceeding in any other jurisdiction to collect the obligations,
     to realize on the Collateral or any other security for the obligations, or
     to enforce a judgment or other court order in favor of the Purchaser. The
     Company expressly submits and consents in advance to such jurisdiction in
     any Proceeding commenced in any such court, and the Company hereby waives
     any objection which it may have based upon lack of personal jurisdiction,
     improper venue or forum non conveniens. The Company hereby waives personal
     service of the summons, complaint and other process issued in any such
     Proceeding and agrees that service of such summons, complaint and other
     process may be made by registered or certified mail addressed to the
     Company at the address set forth in Section 7(g) and that service so made
     shall be deemed completed upon the earlier of the Company's actual receipt
     thereof or three (3) days after deposit in the U.S. mails, proper postage
     prepaid. The parties hereto desire that their disputes be resolved by a
     judge applying such applicable laws. Therefore, to achieve the best
     combination of the benefits of the judicial system and of arbitration, the
     parties hereto waive all rights to trial by jury in any Proceeding brought
     to resolve any dispute, whether arising in contract, tort, or otherwise
     between the Purchaser and/or the Company arising out of, connected with,
     related or incidental to the relationship established between then in
     connection with this Agreement. If either party hereto shall commence a
     Proceeding to enforce any provisions of this Agreement, the Securities
     Purchase Agreement or any other Related Agreement, then the prevailing
     party in such Proceeding shall be reimbursed by the other party for its
     reasonable attorneys' fees and other costs and expenses incurred with the
     investigation, preparation and prosecution of such Proceeding.

          (k) Cumulative Remedies. The remedies provided herein are cumulative
     and not exclusive of any remedies provided by law.

          (l) Severability. If any term, provision, covenant or restriction of
     this Agreement is held by a court of competent jurisdiction to be invalid,
     illegal, void or unenforceable, the remainder of the terms, provisions,
     covenants and restrictions set forth herein shall remain in full force and
     effect and shall in no way be affected, impaired or invalidated, and the
     parties hereto shall use their reasonable efforts to find and employ an
     alternative means to achieve the same or substantially the same result as
     that contemplated by such term, provision, covenant or restriction. It is
     hereby stipulated and declared to be the intention of the parties that they
     would have executed the remaining terms, provisions, covenants and
     restrictions without including any of such that may be hereafter declared
     invalid, illegal, void or unenforceable.

          (m) Headings. The headings in this Agreement are for convenience of
     reference only and shall not limit or otherwise affect the meaning hereof.

                   [Balance of page intentionally left blank;
                             signature page follows]

<PAGE>

         IN WITNESS WHEREOF, the parties have executed this Registration Rights
Agreement as of the date first written above.

AMS HEALTH SCIENCES, INC.                  LAURUS MASTER FUND, LTD.

By:    /s/Jerry W. Grizzle                 By:    /s/David Grin
Name:  Jerry w. Grizzle                    Name:  David Grin
Title: Chairman, President & CEO           Title: Director

                                           Address for Notices:

                                           825 Third Avenue, 14th Floor
                                           New York, NY  10022
                                           Attention:    David Grin
                                           Facsimile:    212-541-4434

<PAGE>

                                    EXHIBIT A

                                 June __, 2006]

UMB Bank, n.a.
Securities Transfer Division
928 Grand Blvd. 5th Floor
Kansas City, MO 64106

Attn:  Jennifer Fuller

       Re: AMS Health Sciences, Inc.Registration Statement on Form S-3

Ladies and Gentlemen:

     As counsel to AMS Health Sciences, Inc., an Oklahoma corporation (the
"Company"), we have been requested to render our opinion to you in connection
with the resale by the individuals or entitles listed on Schedule A attached
hereto (the "Selling Stockholders"), of an aggregate of __________ shares (the
"Shares") of the Company's Common Stock.

     A Registration Statement on Form S-3 under the Securities Act of 1933, as
amended (the "Act"), with respect to the resale of the Shares was declared
effective by the Securities and Exchange Commission on [date]. Enclosed is the
Prospectus dated [date]. We understand that the Shares are to be offered and
sold in the manner described in the Prospectus.

     Based upon the foregoing, upon request by the Selling Stockholders at any
time while the registration statement remains effective, it is our opinion that
the Shares have been registered for resale under the Act and new certificates
evidencing the Shares upon their transfer or re-registration by the Selling
Stockholders may be issued without restrictive legend. We will advise you if the
registration statement is not available or effective at any point in the future.

                                     Very truly yours,

                                     David Ketelsleger, Esq.

<PAGE>

                             Schedule A to Exhibit A

                                                             Shares
     Selling Stockholder                                 Being Offered
     -------------------                                 -------------

Laurus Master Fund, Ltd.

Ascendiant Securities, LLC

Ascendiant Capital Group, LLC                                250,000

<PAGE>
                                  Schedule 6(b)

The Company received a letter from the American Stock Exchange ("AMEX") on
January 12, 2006 giving the Company notice that it did not currently meet the
AMEX's continued listing standards as set forth in Part 10 of the AMEX Company
Guide (the "Company Guide"). Specifically, the Company is not in compliance with
Section 1003(a)(ii) of the Company Guide, which provides that AMEX will consider
suspending or delisting securities of a company that has shareholders' equity of
less than $4,000,000 and has losses from continuing operations and/or net losses
in three out of its four most recent fiscal years. The Company's shareholders'
equity as reported on its Form 10-KSB for the year ended December 31, 2005 was
$2,519,389 and the Company recorded net losses for the 2005, 2004 and 2003
fiscal years.

The Company was required to submit a plan to AMEX to regain compliance with
AMEX's continued listing standards (the "Plan"), which it did on February 13,
2006.

On March 31, 2006, the Company received a letter from the AMEX notifying the
Company that the AMEX has determined that the Company has made a reasonable
demonstration of its ability to regain compliance with AMEX's continued listing
standards by the end of the Plan period, which the AMEX set at July 12, 2007.

During the Plan period, the AMEX will continue the listing of the Company. The
Company is required to provide the AMEX with updates in conjunction with the
Plan as appropriate, but in any event, no later than at each quarter, with the
Company's filing of its Forms 10-QSB with the Securities and Exchange
Commission. Additionally, the AMEX staff will review the Company's operations
periodically for compliance with the Plan. If the Company is not making progress
consistent with the Plan, the AMEX staff will review the circumstances and may
immediately commence delisting proceedings, if necessary.

At the end of the Plan period, July 12, 2007, the Company must be in compliance
with all of the AMEX continued listing standards or the AMEX staff will most
likely initiate delisting proceedings against the Company.

<PAGE>
                                  Schedule 7(b)

Pursuant to the terms of the Company's Engagement Agreement with Ascendiant
Securities, LLC dated March 15, 2006, the Company will issue warrants, the
shares equal to 8% of the securities issuable in connection with this financing
transaction. The shares underlying the warrants and 250,000 shares of restricted
shares due to Ascendiant upon the completion of this transaction contain
piggyback registration rights.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]